adv-biotech-2018-scientifictracks

13 / 13

Page 55
Notes:
conferenceseries.com
Volume 8 Journal of Biotechnology & Biomaterials
ISSN: 2155-952X Adv.Biotech 2018
November 15-17, 2018
November 15-17, 2018 | Berlin, Germany
4th International Conference on
Advances in Biotechnology and Bioscience
Role of curcumin-zinc oxide composite nanoparticles on streptozotocin-induced diabetic rats
Mai Mohamed Raslan1, Sameh Mohamed2, Mohamed D E Abd El Maksoud3 and Khalid El Nesr1
1Beni Suef University, Egypt
2October 6 University, Egypt
3National Research Center, Egypt
Diabetes mellitus (DM) is a chief global public health concern, as it is a tremendously widespread endocrine disease that
causes many complications risking patient’s quality of life. The correlation of diabetes and disturbance of zinc homeostasis
made zinc oxide nanoparticles an attractive therapeutic suggestion. Glucose-phosphorylating enzyme glucokinase (GK)
and glucose transporter GLUT2, had been implicated in glucose metabolism control in DM. Curcumin, the major active
polyphenolic constituent of turmeric rhizomes (Curcuma longa, family Zingiberaceae), shows pleiotropic effects on a wide
spectrum of molecular targets. In DM, curcumin exerts hypoglycemic effects via different mechanisms including GK and
GLUT2 gene expression. The use of nanoparticles in medicine is an attractive proposition. The current study aims to evaluate
the potential activities of prepared and characterized curcumin nanoparticles (Curc-NP), zinc oxide nanoparticles (ZnO-NP),
and curcumin-zinc oxide composite nanoparticles (Curc-ZnO-NP) on streptozotocin (STZ)-induced diabetic rats (10 rats/
group). The potential defending character of every treatment against diabetic rats was evaluated by investigating different
biochemical (glucose, insulin, urea, creatinine, HbA1-C, AST and ALT) and histopathological parameters as well as protein
expression of GK and GLUT2 in the pancreas and livers of diabetic rats. Adult Wistar albino rats (180-200 g) were injected
intraperitoneally with a freshly prepared STZ single dose (50 mg/kg b.w.) for the induction of type-2 DM. Diabetic rats were
treated orally with a daily dose of 50 mg/kg b.w. of Curc-NP, and 10 mg/kg b.w. of ZnO-NP, Curc-ZnO-NP, and diamicron
(traditional anti-diabetic agent) for 21 days. All treatments showed significant reduced blood glucose, elevated insulin levels,
regulated GLUT-2 and glucokinase genes, however, Curc-ZnO-NP showed the most potent anti-diabetic activities comparable
to normal rats. The histopathological findings confirm the biochemical and molecular data recommending Curc-ZnO-NP as
a potential anti-diabetic agent.
Biography
Mai M. Raslan works as a lecturer at Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University,
Egypt. Mai Raslan has completed her PhD in Pharmacognosy, Faculty of Pharmaceutical Sciences, Cairo University, Egypt in 2011.
J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C6-104